U.S. markets closed
  • S&P Futures

    4,362.25
    +1.25 (+0.03%)
     
  • Dow Futures

    34,239.00
    +7.00 (+0.02%)
     
  • Nasdaq Futures

    14,875.00
    +5.50 (+0.04%)
     
  • Russell 2000 Futures

    1,794.70
    +2.00 (+0.11%)
     
  • Crude Oil

    90.30
    +0.27 (+0.30%)
     
  • Gold

    1,943.70
    -1.90 (-0.10%)
     
  • Silver

    23.81
    -0.04 (-0.16%)
     
  • EUR/USD

    1.0654
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     
  • Vix

    17.20
    -0.34 (-1.94%)
     
  • GBP/USD

    1.2246
    +0.0006 (+0.05%)
     
  • USD/JPY

    148.4280
    +0.0680 (+0.05%)
     
  • Bitcoin USD

    26,132.93
    -451.65 (-1.70%)
     
  • CMC Crypto 200

    558.25
    -9.80 (-1.73%)
     
  • FTSE 100

    7,683.91
    +5.29 (+0.07%)
     
  • Nikkei 225

    32,487.08
    +84.67 (+0.26%)
     

Sanofi/Regeneron's Libtayo Wins FDA Approval For A Type Of Skin Cancer

  • Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) immunotherapy Libtayo (cemiplimab-rwlc) has scored approval from the FDA for the treatment of advanced basal cell carcinoma (BCC), the most common type of skin cancer in the U.S.

  • The FDA has indicated Libtayo for treating previously-treated, advanced BCC patients who have already received a hedgehog pathway inhibitor (HHI) or who cannot be treated with an HHI.

  • The PD-1 inhibitor has been granted full approval for patients with locally advanced BCC and accelerated approval for patients with metastatic BCC, which has spread to other parts of the body.

  • In 2018, Libtayo was approved as the first systemic treatment for metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

  • Price Action: REGN closed 0.8% down at $490.68, while, SNY closed 0.5% higher at $48.86.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.